King Bio initiated the recall after discovering a small amount of products tested positive for microbial contamination.
The children’s medications are intended to treat a range of common illnesses, such as fever, cough and ear aches. King Bio produced the recalled products between August 2017 and April 2018. They were shipped to distributors and retail stores nationwide between August 2017 and July 2018.
King Bio sent letters to customers and distributors notifying them of the recall and is arranging for the return and replacement of affected medicines.
No illnesses or illnesses have been reported.
More articles on Pharmacy:
6 things to know about the EpiPen shortage
The No. 1 issue for biopharma: Public distrust
Medicare could have saved $925M by swapping brand-name combo drugs for generics
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.